After calling for a major discount for Pfizer’s popular transthyretin amyloid cardiomyopathy (ATTR-CM) med tafamidis, a U.S.

Sanofi is now in “exclusive negotiations” with U.S. private equity firm Clayton, Dubilier & Rice (CD&R) to sell a 50% ...

Following a series of layoff rounds this year, Takeda is once again pruning its headcount in the Bay State. | As part of a ...

In addition to Nucleus’ facility at the Mayo Clinic in Rochester, Minnesota, these sites will bring radiopharmaceutical ...

As Novo Nordisk’s injectable diabetes-obesity duo Ozempic and Wegovy grab all the limelight, an oral version of the ...

Activist investor Starboard Value, which picked up a $1 billion stake in Pfizer earlier this month, now reportedly has ...

Novo Holdings is encountering more resistance as it aims to close its $16.5 billion acquisition of pharma manufacturing giant ...

As recovery efforts at the North Carolina plant hit by Hurricane Helene move at an “encouraging pace,” Baxter International ...

After a prior rejection, Astellas can head into the weekend celebrating a class-first FDA approval for its new gastric cancer ...

Since 2021, the Obesity Action Coalition (OAC) has led a national public awareness campaign against weight bias with a goal ...

After hitting a wall with the FDA last year, Novo Nordisk has picked up backing from European drug reviewers for its novel ...

With Gilead sprinting to a likely approval next year for its long-acting pre-exposure | With GSK girding for competition from ...